Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.
Stem cells are generally influenced by a microenvironmental niche, typically comprised of epithelial and mesenchymal cells and extracellular substrates. Many attempts have been made to produce culture systems that mimic normal intestinal epithelial growth and differentiation.
Patients with celiac disease have a pathological reaction to gluten and have either HLA-DQ2+ (90%) or HLA-DQ8+, but expression of these MHC class II haplotypes is not sufficient and other factors are necessary for the development of celiac sprue.
Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Researchers at Stanford University have discovered a way to enhance the effectiveness of CAR-T cell therapeutics through inducing a more memory-like phenotype.
Stanford scientists have discovered that blocking an immune receptor signal can lead to increased fat uptake and weight reduction in patients suffering from obesity and associated diseases.
Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
Stanford scientists have developed a strategy that enables simultaneous and combinatorial genetic screening across different types of genetic perturbations (gene knockouts, knock-ins, overexpression, and gene domain modification).
Stanford researchers have developed a strategy for engineering next-generation cell therapies where gene knock-in is tightly coupled to gene knockout, preventing dangerous side effects associated with cells that have the knockout in the absence of the knock-in and vice versa.
Researchers at Stanford University have developed a method and composition of immunomodulatory compounds that prevent and reverse T cell exhaustion, improving on existing CAR T cell therapies.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.